NewTimeSpace News: SSY GROUP (02005.HK) announced that Baloxavir Marboxil active pharmaceutical ingredient (API) of the Group has been approved and registered by NMPA for use in marketed formulations, making the Company the third domestic enterprise to obtain the approval. Baloxavir Marboxil is mainly indicated for the treatment of influenza A and B viruses.
NewTimeSpace (newtimespace.com) News, On July 13, 2026, Hong Kong large model concept stocks diverged in morning trading, with stocks such as Zhipu (2513.HK), Mininglamp Technology (2718.HK), and Kuaishou (1024.HK) leading the gains.As of 09:48, Zhipu (2513.HK) was quoted at HK$1,833.000, achieving an intraday surge of 11.77% and leading the gains in the large model concept stock theme.
NewTimeSpace News: ABBISKO-B (02256.HK) announced on 13 July that ABSK211, an oral pan-KRAS inhibitor, has obtained FDA clearance for Phase I clinical development in advanced solid tumours with KRAS alterations. Preclinical data demonstrate broad potency against multiple KRAS variants and synergistic anti-tumour efficacy in combination regimens. The candidate has secured IND approvals in both China and the U.S. The Company reminds investors of uncertainties in drug development and approval processes.
NewTimeSpace News: Longbio-B (01779.HK) announced on 13 July that LP-003, an in-house developed anti-IgE antibody, has obtained clearance from the U.S. FDA to launch clinical trials for peanut allergy. The global food allergy patient population is projected to reach 457 million by 2030. In China, the Company has secured IND approvals or initiated clinical studies of LP-003 across multiple allergic indications. The Company cautions uncertainties exist regarding successful development and commercialisation of the asset.
NewTimeSpace News: INSILICO (03696.HK) announced on 13 July that the Group has entered into a new strategic cooperation for central nervous system drug research and development with Cosmo Pharmaceutical Holdings Limited. Leveraging INSILICO’s AI platform and Cosmo’s profound disease expertise, both parties will jointly advance innovative drug development. INSILICO is eligible to receive milestone payments of up to approximately RMB1.2 billion in aggregate, plus net sales royalties. The Company reminded investors that forward-looking statements are not guaranteed to materialise and shareholders should exercise caution when trading shares.
newtimespace.com reports, BASiC Semiconductor will moderately adjust selling prices for certain products from Q3 2026, with increases of up to 25%, citing tight supply-demand balances driven by AI and new energy vehicle demand. The adjustment aims to support R&D investment and ensure supply stability, with implementation to be determined based on product category and order size.
This week, the broader Hong Kong market advanced, but LLM concept stocks exhibited extreme divergence. Alibaba led the sector with a 17%+ gain, driven by Agent product consolidation and strong cloud revenue forecasts, while Tencent and Meituan posted solid growth. Conversely, MiniMax plunged over 22% weighed down by lock-up expirations and a massive financing plan. KNOWLEDGE ATLAS dropped 8.5% amid late-week profit-taking, despite completing a record HKD 31.4 billion placement. Industry developments were robust: MIIT projected China's core AI industry to exceed RMB 1.2 trillion in 2025; OpenAI fully launched the GPT-5.6 series; Tencent unveiled Hunyuan Hy3 and Agent Bucket; and regulators issued new compliance measures for AI personified interactive services, accelerating the industry's shift toward standardized commercialization.
On July 10, Hong Kong equities advanced initially before pulling back, with the LLM and semiconductor sectors undergoing a sharp correction. KNOWLEDGE ATLAS plunged over 19%, while MiniMax and XUNCE also suffered heavy losses; GigaDevice crashed 21% ahead of a major lock-up expiration. On the industry front, OpenAI officially opened its full GPT-5.6 series (Sol, Terra, Luna) to the public, establishing an astronomically-themed product matrix with distinct iteration cadences. In capital markets, MiniMax announced a combined equity placement and convertible bond issuance to raise over HKD 16 billion, heavily betting on compute infrastructure and model R&D. Furthermore, Tencent Cloud launched Agent Bucket, providing isolated cloud storage solutions for massive AI agents, thereby fortifying the foundational infrastructure for agentic ecosystems.
NewTimeSpace News: SBP GROUP (01177.HK) announced on 10 July that the New Drug Application (NDA) for TQB3454 Tablets, an in-house developed Category 1 innovative IDH1 inhibitor, has been accepted by CDE under NMPA for the treatment of advanced biliary tract cancer harbouring IDH1 mutations. The candidate obtained Breakthrough Therapy Designation in April 2023 and was included under Priority Review in May 2026. Its Phase III trial delivered significant improvements in PFS and OS, marking globally the second and domestically the first positive Phase III study for an IDH1 inhibitor in biliary tract cancer. No targeted therapy of the same target has yet been approved in China.
NewTimeSpace News: SSY GROUP (02005.HK) announced on 10 July that Propylthiouracil Tablets (50mg) and Calcium Gluconate and Sodium Chloride Injection have secured drug registration approvals issued by NMPA, both deemed to have passed consistency evaluation. Propylthiouracil Tablets are the third domestically approved product of this kind, indicated for hyperthyroidism. The injection is used for acute hypocalcaemia, magnesium poisoning and fluoride poisoning.
NewTimeSpace News: HENLIUS (02696.HK) announced on 10 July that the Phase I clinical trial application for self-developed HLX37 (recombinant humanized anti-PD-L1/anti-VEGF bispecific antibody injection) in combination with chemotherapy or HLX43 for injection (PD-L1 targeted ADC) for advanced/metastatic solid tumours has been approved by NMPA. No similar combination regimen has been approved globally to date. The Company cautions there is no guarantee of successful development and commercialisation.
NewTimeSpace News: HENGRUI PHARMA (01276.HK) announced on 10 July that it has received a Complete Response Letter (CRL) from the US FDA regarding the BLA for camrelizumab for injection combined with apatinib as first-line treatment of unresectable or metastatic hepatocellular carcinoma. The feedback mainly concerns cGMP inspection observations at the apatinib manufacturing site and does not involve clinical data, safety or efficacy issues. Final analysis of the CARES-310 trial demonstrated median overall survival of 23.8 months, the longest median OS reported for first-line liver cancer treatment to date. The Group will communicate actively with the FDA and partner Elevar Therapeutics to clarify next submission plans, while noting there is uncertainty over approval.
NewTimeSpace News: On 10 July 2026, RoboSense (02498.HK) trended upward in the afternoon session. As of 15:24, the stock traded at HK$23.50, representing a 0.17% gain. The Company’s total LiDAR shipments reached 388,900 units in the second quarter of 2026.
NewTimeSpace (newtimespace.com) reported that on July 10, 2026, semiconductor‑related themes continued to rise, with HUA HONG GRACE (01347.HK) extending its upward momentum. As of 13:36, the stock was quoted at HKD 208.800, up 3.47%.
NewTimeSpace (newtimespace.com) reported that on July 10, 2026, the humanoid robot theme rallied sharply, with Midea Group (00300.HK) fluctuating slightly higher. As of 13:17, the stock was quoted at HKD 88.800, up 0.40%.
NewTimeSpace News: SSY GROUP (02005.HK) announced that a total of 95 varieties (141 specifications) of the Group’s products have been incorporated into the National Essential Medicines List (2026 Edition), including 32 newly added varieties (37 specifications). The catalogue will take effect on 1 September 2026 and is expected to exert a positive impact on the Group’s growth and business development.
